The TAILORx Breast Cancer Trial

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Woman Looking Out Window

TAILORx seeks to incorporate a molecular profiling test into clinical decision making for breast cancer patients.

Credit: iStock

The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, is examining whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.

The majority of women with early-stage breast cancer are advised to receive chemotherapy in addition to radiation and hormonal therapy, yet research has not demonstrated that chemotherapy benefits all of them equally. TAILORx seeks to incorporate a molecular profiling test (a technique that examines many genes simultaneously) into clinical decision making, and thus spare women unnecessary treatment if chemotherapy is not likely to be of substantial benefit. TAILORx is one of the first trials to examine a methodology for personalizing cancer treatment.

The study has randomized more than 10,000 women at more than 1,000 sites in the United States and Canada. Women recently diagnosed with estrogen-receptor and/or progesterone-receptor positive, Her2/neu-negative breast cancer that had not yet spread to the lymph nodes were eligible for the study. (See a summary of the TAILORx protocol for more information.) 

The women were categorized into three recurrence risk groups depending on their score on the gene expression test. Women in the lowest-risk group were assigned to treatment with hormone therapy, women in the intermediate-risk group were randomly assigned to receive hormone therapy alone or hormone therapy plus adjuvant chemotherapy, and women in the highest-risk group were assigned to receive hormone therapy plus adjuvant chemotherapy.

In September 2015, results were reported from an analysis of the women in the lowest- risk group. The findings showed that at 5 years, rates of distant relapse-free survival were 99.3 percent, of invasive disease free survival were 93.8 percent, and of overall survival were 98.0 percent. These results provide prospective evidence that the gene expression test identifies women with a low risk of recurrence who can be spared chemotherapy. (See the clinical trial result summary for more information.)

TAILORx is sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), and is coordinated by the Eastern Cooperative Oncology Group (now the ECOG-ACRIN Cancer Research Group). All of the NCI-sponsored clinical trials groups that perform breast cancer research studies have collaborated in the trial’s development and are participating in this study.

  • Updated: September 28, 2015

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source and a link to this page included, e.g., “The TAILORx Breast Cancer Trial was originally published by the National Cancer Institute.”

Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artists, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.